Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amantadine + levodopa + carbidopa
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amantadine + levodopa + carbidopa is a combination therapy being investigated by Weill Medical College of Cornell University for the treatment of disorders of consciousness (DOC) resulting from severe traumatic brain injury (TBI). This pharmacological challenge aims to address the downregulation of the anterior forebrain mesocircuit, a key mechanism in DOC, by modulating synaptic background activity. Amantadine acts as an N-methyl-D-aspartate (NMDA) receptor antagonist and promotes dopamine release, while levodopa serves as a metabolic precursor to dopamine, and carbidopa prevents its peripheral degradation by inhibiting aromatic-L-amino-acid decarboxylase. By increasing dopamine availability and regulating glutamatergic homeostasis, the combination is intended to restore synaptic activity and improve arousal and goal-directed behavior in post-traumatic patients.
- Other names
- amantadine + L-DOPAamantadine + levodopaamantadine + levodopa + carbidopa
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)DDC (Aromatic L-amino acid decarboxylase)DRD (Dopamine receptors)
Beyond the preview
Go deeper on amantadine + levodopa + carbidopa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amantadine + levodopa + carbidopa.